 |
42 Diseases |  |
114 Trials |
|
114 Trials |  |
1648 News |  |
| «12...1415161718192021222324...3031» |
- | pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients (clinicaltrials.gov) - Aug 22, 2019
P2, N=254, Active, not recruiting, Sponsor: TTY Biopharm
Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> May 2023 | Trial primary completion date: Jul 2018 --> Oct 2019
- | Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Trial initiation date, Combination therapy, Tumor mutational burden, IO biomarker, Metastases: Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) (clinicaltrials.gov) - Aug 19, 2019
P2, N=115, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> May 2023 | Trial primary completion date: Jul 2018 --> Oct 2019 Not yet recruiting --> Recruiting | Initiation date: Nov 2019 --> Jun 2019
- | pegylated liposomal doxorubicin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Biomarker, New trial: Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 13, 2019
P, N=24, Recruiting, Sponsor: Fox Chase Cancer Center
- | etrumadenant (AB928) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date, IO biomarker: ARC-2: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (clinicaltrials.gov) - Jul 31, 2019
P1, N=214, Recruiting, Sponsor: Arcus Biosciences, Inc.
Not yet recruiting --> Recruiting | Initiation date: Nov 2019 --> Jun 2019 Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Feb 2022
- | eprenetapopt (APR-246) / Aprea
Trial completion: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 (clinicaltrials.gov) - Jul 30, 2019
P1/2, N=200, Completed, Sponsor: Aprea Therapeutics AB
Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Feb 2022 Active, not recruiting --> Completed
- | eprenetapopt (APR-246) / Aprea
Trial completion, Enrollment change: p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 (clinicaltrials.gov) - Jul 29, 2019
P2, N=36, Completed, Sponsor: Aprea Therapeutics AB
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=25 --> 36
- | Bavencio (avelumab) / EMD Serono, Trodelvy (sacituzumab govitecan-hziy) / Gilead, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Tumor mutational burden, Metastases: InCITe: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 28, 2019
P2, N=150, Recruiting, Sponsor: Hope Rugo, MD
Active, not recruiting --> Completed | N=25 --> 36 Not yet recruiting --> Recruiting
- | carboplatin / Generic mfg., cyclophosphamide / Generic mfg., paclitaxel / Generic mfg.
Enrollment open: Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer (clinicaltrials.gov) - Jul 11, 2019
P2, N=50, Recruiting, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting Suspended --> Recruiting
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: BV mini CHP: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jul 5, 2019
P2, N=24, Recruiting, Sponsor: Patrick Reagan
Suspended --> Recruiting Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2019 --> Jun 2020
- | Neulasta (pegfilgrastim) / Roche
Trial completion date, Trial primary completion date: PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 2, 2019
P=N/A, N=70, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2019 --> Jun 2020 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: 19-C-0103: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (clinicaltrials.gov) - Jun 27, 2019
P2, N=32, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 Not yet recruiting --> Recruiting
- || anetumab ravtansine (BAY 94-9343) / Bayer
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer (clinicaltrials.gov) - Jun 27, 2019
P1, N=65, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Feb 2021 --> Nov 2019 | Trial primary completion date: Jan 2021 --> Oct 2019
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: 19-C-0103: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (clinicaltrials.gov) - Jun 23, 2019
P2, N=32, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial completion date: Feb 2021 --> Nov 2019 | Trial primary completion date: Jan 2021 --> Oct 2019 Trial completion date: Jul 2021 --> Jul 2025
- || Herceptin (trastuzumab) / Roche
New P1/2 trial: Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer (clinicaltrials.gov) - Jun 20, 2019
P1/2, N=40, Not yet recruiting, Sponsor: Peking Union Medical College
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Jun 17, 2019
P1/2, N=48, Recruiting, Sponsor: Advenchen Laboratories, LLC
Trial completion date: Jul 2021 --> Jul 2025 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- |||||| New trial, Real-world evidence, Real-world: Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer. (clinicaltrials.gov) - Jun 12, 2019
P, N=1050, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | pegylated liposomal doxorubicin / Generic mfg.
New P1 trial: To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames (clinicaltrials.gov) - Jun 4, 2019
P1, N=500, Not yet recruiting, Sponsor: Sutphin Drugs
- |||| Bavencio (avelumab) / EMD Serono, Trodelvy (sacituzumab govitecan-hziy) / Gilead, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
New P2 trial, Tumor mutational burden, Metastases: InCITe: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (clinicaltrials.gov) - Jun 2, 2019
P2, N=150, Not yet recruiting, Sponsor: Hope Rugo, MD
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: 19-C-0103: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (clinicaltrials.gov) - May 28, 2019
P2, N=32, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Trial suspension, PD(L)-1 Biomarker, IO biomarker: NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 22, 2019
P2/3, N=488, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Recruiting --> Suspended
- |||| Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen
Trial completion date, Trial primary completion date, Metastases: FORWARD I: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov) - May 20, 2019
P3, N=366, Active, not recruiting, Sponsor: ImmunoGen, Inc.
Recruiting --> Suspended Trial completion date: Jun 2020 --> Jan 2020 | Trial primary completion date: Jun 2019 --> Jan 2019
- | New P3 trial, Head-to-Head: Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma (clinicaltrials.gov) - May 15, 2019
P3, N=244, Recruiting, Sponsor: Peking University
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma
New P3 trial: Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin?PLD) (clinicaltrials.gov) - May 13, 2019
P3, N=272, Recruiting, Sponsor: Fudan University
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
New P2 trial, Tumor mutational burden, Metastases: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients With metastatic hormone receptor positive breast cancer (EUDRACT) - May 11, 2019
P2, N=75, Ongoing, Sponsor: Oslo University Hospital
- || etrumadenant (AB928) / Arcus Biosci, Gilead
Enrollment change, Trial completion date, Trial primary completion date, IO biomarker: ARC-2: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (clinicaltrials.gov) - May 1, 2019
P1, N=214, Recruiting, Sponsor: Arcus Biosciences, Inc.
Trial completion date: Jun 2020 --> Jan 2020 | Trial primary completion date: Jun 2019 --> Jan 2019 N=98 --> 214 | Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2020
- || pegylated liposomal doxorubicin / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: CAELYX (clinicaltrials.gov) - May 1, 2019
P2, N=63, Active, not recruiting, Sponsor: European Institute of Oncology
N=98 --> 214 | Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- || New P2 trial, Metastases: Phase ? Study of Pegylated Liposomal Doxorubicin?PLD?Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 30, 2019
P2, N=30, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date, Metastases: KEYDOX: Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer (clinicaltrials.gov) - Apr 24, 2019
P1b, N=15, Recruiting, Sponsor: Shaare Zedek Medical Center
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Apr 2019
- | Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma (clinicaltrials.gov) - Apr 20, 2019
P2, N=25, Active, not recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Apr 2019 Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019
- | Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Trial completion date, Trial primary completion date: Doxil, Bevacizumab and Temsirolimus Trial (clinicaltrials.gov) - Apr 20, 2019
P1, N=200, Completed, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019 Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Mar 2019 | Trial primary completion date: Aug 2019 --> Mar 2019
- ||||| AZD7648 / AstraZeneca
New P1/2 trial, Combination therapy, Monotherapy, Metastases: A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. (clinicaltrials.gov) - Apr 9, 2019
P1/2, N=230, Not yet recruiting, Sponsor: AstraZeneca
- | Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Combination therapy, Tumor mutational burden, IO biomarker, Metastases: Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) (clinicaltrials.gov) - Apr 9, 2019
P2, N=115, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || amcasertib (BBI-503) / Sumitomo Pharma
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer (clinicaltrials.gov) - Mar 27, 2019
P1/2, N=165, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Mar 2019 | Trial primary completion date: Aug 2019 --> Mar 2019 Trial primary completion date: Dec 2018 --> May 2019
- | pegylated liposomal doxorubicin / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors (clinicaltrials.gov) - Mar 19, 2019
P1, N=0, Withdrawn, Sponsor: Theodore Laetsch
Trial primary completion date: Dec 2018 --> May 2019 N=14 --> 0 | Trial completion date: Dec 2020 --> Mar 2019 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2019 --> Mar 2019
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial completion date, Trial primary completion date: Brentuximab for Newly Diagnosed Hodgkin Disease (clinicaltrials.gov) - Mar 13, 2019
P2, N=40, Recruiting, Sponsor: Mitchell Cairo
N=14 --> 0 | Trial completion date: Dec 2020 --> Mar 2019 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2019 --> Mar 2019 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma
Trial completion, Combination therapy: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 12, 2019
P1, N=16, Completed, Sponsor: Gynecologic Oncology Group
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- ||| nibrozetone (RRx-001) / EpicentRx
Enrollment change: RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) (clinicaltrials.gov) - Mar 6, 2019
P2, N=213, Recruiting, Sponsor: EpicentRx, Inc.
Active, not recruiting --> Completed N=135 --> 213
- || farletuzumab (MORAB-003) / Eisai
Trial completion date, Combination therapy: MORAb-003-011: A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer (clinicaltrials.gov) - Mar 5, 2019
P2, N=215, Active, not recruiting, Sponsor: Eisai Inc.
N=135 --> 213 Trial completion date: May 2019 --> Sep 2021
- | pegylated liposomal doxorubicin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Real-world evidence, Real-world effectiveness, Real-world: Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Feb 28, 2019
P=N/A, N=432, Completed, Sponsor: Konkuk University Medical Center
Trial completion date: May 2019 --> Sep 2021 Recruiting --> Completed | N=900 --> 432 | Trial completion date: Apr 2019 --> Dec 2018
- ||| pegylated liposomal doxorubicin / Generic mfg.
Enrollment change, Metastases: Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients (clinicaltrials.gov) - Feb 21, 2019
P4, N=288, Completed, Sponsor: Spanish Breast Cancer Research Group
Recruiting --> Completed | N=900 --> 432 | Trial completion date: Apr 2019 --> Dec 2018 N=154 --> 288
- |||| Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen
Trial completion date, Trial primary completion date, Metastases: FORWARD I: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 16, 2019
P3, N=333, Active, not recruiting, Sponsor: ImmunoGen, Inc.
N=154 --> 288 Trial completion date: Feb 2019 --> Jun 2020 | Trial primary completion date: Nov 2018 --> Jun 2019
- | pegylated liposomal doxorubicin / Generic mfg.
Trial primary completion date, Metastases: Metronomic PLD in Patients With Primary Endocrine Resistant ABC (clinicaltrials.gov) - Feb 16, 2019
P2, N=46, Recruiting, Sponsor: Fudan University
Trial completion date: Feb 2019 --> Jun 2020 | Trial primary completion date: Nov 2018 --> Jun 2019 Trial primary completion date: Dec 2018 --> Dec 2019
- ||||||| Trial completion, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 6, 2019
P3, N=581, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- || anetumab ravtansine (BAY 94-9343) / Bayer
Trial completion date, Trial primary completion date, Combination therapy: Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer (clinicaltrials.gov) - Jan 31, 2019
P1, N=71, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial completion date: Sep 2020 --> Feb 2021 | Trial primary completion date: Aug 2020 --> Jan 2021
- |||||| Zejula (niraparib) / GSK, J&J, Tecentriq (atezolizumab) / Roche
Enrollment open, IO biomarker: ANITA: Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Jan 29, 2019
P3, N=414, Recruiting, Sponsor: Grupo Espa
Trial completion date: Sep 2020 --> Feb 2021 | Trial primary completion date: Aug 2020 --> Jan 2021 Not yet recruiting --> Recruiting
- ||| farletuzumab (MORAB-003) / Eisai
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: MORAb-003-011: A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer (clinicaltrials.gov) - Jan 23, 2019
P2, N=215, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> May 2019 | Trial primary completion date: Sep 2019 --> May 2019
- | siplizumab (TCD601) / ITBMed, Rituxan (rituximab) / Roche
Trial completion date: Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas (clinicaltrials.gov) - Jan 22, 2019
P1, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> May 2019 | Trial primary completion date: Sep 2019 --> May 2019 Trial completion date: Oct 2019 --> Oct 2020
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov) - Jan 22, 2019
P1, N=52, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2019 --> Oct 2020 Trial completion date: Jun 2022 --> Jun 2023
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov) - Jan 18, 2019
P1, N=52, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2022 --> Jun 2023 Trial completion date: Jun 2023 --> Jun 2022
- | bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg.
Trial primary completion date: Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia (clinicaltrials.gov) - Jan 16, 2019
P2, N=25, Active, not recruiting, Sponsor: Joseph Tuscano
Trial completion date: Jun 2023 --> Jun 2022 Trial primary completion date: Dec 2018 --> Jul 2019